Compugen Ltd.
CGEN
Price:
$1.925
Market Cap:
$172.36M
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical ...[Read more]
Industry
Biotechnology
IPO Date
2000-08-11
Stock Exchange
NASDAQ
Ticker
CGEN
The ROE as of September 2024 (TTM) for Compugen Ltd. (CGEN) is -16.10%
According to Compugen Ltd.’s latest financial reports and current stock price. The company's current ROE is -16.10%. This represents a change of 230.01% compared to the average of -4.88% of the last 4 quarters.
Compugen Ltd. (CGEN) Historical ROE (quarterly & annually)
How has CGEN ROE performed in the past?
The mean historical ROE of Compugen Ltd. over the last ten years is -46.66%. The current -16.10% ROE has changed -65.50% with respect to the historical average. Over the past ten years (40 quarters), CGEN's ROE was at its highest in in the December 2023 quarter at 14.82%. The ROE was at its lowest in in the December 2017 quarter at -31.78%.
Average
-46.66%
Median
-37.09%
Minimum
-126.52%
Maximum
-10.47%
Compugen Ltd. (CGEN) ROE by Quarter and Year
Discovering the peaks and valleys of Compugen Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 155.07%
Maximum Annual ROE = -10.47%
Minimum Annual Increase = -76.30%
Minimum Annual ROE = -126.52%
| Year | ROE | Change |
|---|---|---|
| 2023 | -28.61% | -34.05% |
| 2022 | -43.38% | 40.78% |
| 2021 | -30.81% | 35.38% |
| 2020 | -22.76% | -68.10% |
| 2019 | -71.34% | 17.56% |
| 2018 | -60.68% | -52.04% |
| 2017 | -126.52% | 155.07% |
| 2016 | -49.60% | 121.15% |
| 2015 | -22.43% | 114.25% |
| 2014 | -10.47% | -76.30% |
Compugen Ltd. (CGEN) Average ROE
How has CGEN ROE performed in the past?
The current ROE of Compugen Ltd. (CGEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.26%
5-year avg
-39.38%
10-year avg
-46.66%
Compugen Ltd. (CGEN) ROE vs. Peers
How is CGEN’s ROE compared to its peers?
Compugen Ltd.’s ROE is greater than BiomX Inc. (-121.74%), greater than Pluri Inc. (-250.46%), greater than Surface Oncology, Inc. (-113.52%), greater than BioLineRx Ltd. (-225.62%), greater than iTeos Therapeutics, Inc. (-18.19%), greater than Icosavax, Inc. (-41.24%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than VectivBio Holding AG (-56.92%), greater than Annexon, Inc. (-44.68%), greater than Allogene Therapeutics, Inc. (-53.76%), greater than Beam Therapeutics Inc. (-16.22%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Caribou Biosciences, Inc. (-34.76%), greater than Editas Medicine, Inc. (-62.61%), less than Can-Fite BioPharma Ltd. (0%), greater than ImmuCell Corporation (-111.34%), greater than Evogene Ltd. (-16.35%), greater than CollPlant Biotechnologies Ltd. (-189.58%), greater than null (-65.98%),
| Company | ROE | Market cap |
|---|---|---|
| -121.74% | $17.00M | |
| -250.46% | $28.31M | |
| -113.52% | $65.08M | |
| -225.62% | $56.61M | |
| -18.19% | $435.89M | |
| -41.24% | $769.04M | |
| -81.10% | $4.12B | |
| -56.92% | $1.06B | |
| -44.68% | $749.62M | |
| -53.76% | $575.06M | |
| -16.22% | $2.13B | |
| -71.60% | $984.41M | |
| -34.76% | $182.56M | |
| -62.61% | $314.65M | |
| 0% | $13.51M | |
| -111.34% | $28.04M | |
| -16.35% | $13.81M | |
| -189.58% | $57.27M | |
| -65.98% | $0 |
Build a custom stock screener for Compugen Ltd. (CGEN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Compugen Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Compugen Ltd. (CGEN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Compugen Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Compugen Ltd.'s ROE?
How is the ROE calculated for Compugen Ltd. (CGEN)?
What is the highest ROE for Compugen Ltd. (CGEN)?
What is the 3-year average ROE for Compugen Ltd. (CGEN)?
What is the 5-year average ROE for Compugen Ltd. (CGEN)?
How does the current ROE for Compugen Ltd. (CGEN) compare to its historical average?